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Abstract 
Lipoprotein(a) [Lp(a)] - an established risk factor for vascular disease, has been suggested to be 
associated with risk of dementia, however no prospective evidence exists to support this finding. We 
aimed to assess the association of lipoprotein(a) [Lp(a)] with dementia risk. Lp(a) concentration was 
assessed at baseline in a prospective cohort of 2,532 men aged 42-61 years. During a median follow-up of 
24.9 years, 228 new cases of dementia were recorded. Lp(a) was approximately log-linearly associated 
with dementia risk. In age-adjusted analysis, the hazard ratio for dementia in a comparison of extreme 
quartiles of Lp(a) levels was 0.68 (95% CI: 0.47-0.99), which persisted after adjustment for several 
physical measures, history of coronary heart disease, smoking status, history of diabetes, serum lipids, 
alcohol consumption, and socio-economic status 0.68 (0.46-0.99). Lp(a) is protective of future dementia 
risk in a middle-aged male Caucasian population. Further research is needed replicate these findings. 
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Introduction 
Dementia is a growing public health concern especially with an aging population.(1) Though ageing and 
the APOE gene (encoding apolipoprotein E, ApoE) are major risk factors for dementia,(2) its 
pathogenesis is still not fully understood. Lipoprotein (a) [Lp(a)], which consists of a low-density 
lipoprotein (LDL)-like core lipoprotein covalently linked to glycoprotein Apo(a),(3) is a causal risk factor 
for vascular disease; (4) which is known to be associated with cognitive decline.(5) Emerging evidence 
suggests Lp(a) may be linked with the development of dementia. However, data on the association 
between Lp(a) and risk of dementia are sparse and inconsistent. Whereas some studies have shown higher 
levels of Lp(a) to be linked with increased dementia risk,(6) some have shown a protective effect,(6-8) 
and others have shown no association at all.(9) However, due to the case-control design of these previous 
studies, the temporal sequence of the relationship between Lp(a) and cognitive decline has not been 
established and whether elevated Lp(a) levels increase or decrease the risk of future dementia is currently 
unknown. In this context, our aim was to assess the prospective nature of the association between plasma 
Lp(a) and risk of dementia in a population-based cohort of 2,532 apparently healthy middle-aged men 
from eastern Finland.  
 
Methods 
Participants in the study were men aged 42-61 years recruited into the Kuopio Ischemic Heart Disease 
(KIHD) study in eastern Finland, previously described.(10) The Research Ethics Committee of the 
University of Eastern Finland approved the study, and each participant gave written informed consent. 
Lipoprotein(a) concentrations were measured from frozen plasma samples stored at -20° C for 2-6 years, 
using  a radioimmunoassay (Mercodia Apo(a) RIA, Mercodia AB, Uppsala, Sweden). Details on 
dementia screening and diagnosis have been described in a recent report.(10) Briefly, participants were 
first screened using the Mini-Mental State Examination and Geriatric Mental State at baseline 
examination and every year, followed by further cognitive testing of screen-positives. An independent 
committee of neurologists of the KIHD study, masked to clinical data, reviewed all potential cases of 
dementia to obtain a consensus on the diagnosis and aetiology. Hazard ratios (HRs) with 95% confidence 
intervals (CIs) were calculated using Cox proportional hazard models.  All statistical analyses were 
conducted using Stata version 14 (Stata Corp, College Station, Texas). 
 
Results 
The mean age at entry was 53 (SD, 5) years. The median (interquartile range) of Lp(a) at baseline was 
9.66 (3.78-22.56) mg/dl. During a median follow-up of 24.9 years, 228 dementia cases were recorded. In 
analysis adjusted for conventional risk factors, there was an approximately log-linear association of Lp(a) 
with incident dementia (Figure). In age-adjusted analysis, the HR for dementia comparing the top quartile 
with the bottom quartile of baseline loge Lp(a) levels was 0.68 (95% CI: 0.47 to 0.99; P =0.044). The 
association remained consistent on further adjustment for body mass index, systolic blood pressure, 
prevalent coronary heart disease, smoking status, history of diabetes mellitus, total cholesterol, high-
density lipoprotein cholesterol, alcohol consumption, socio-economic status, and physical activity 0.68 
(95% CI: 0.46 to 0.99; P = 0.044). These findings remained unchanged after accounting for incident 
coronary events (Table). The total number of all-cause mortality events recorded during follow-up was 
1202, of which 559 were CVD deaths. In analyses that adjusted for all-cause mortality and CVD mortality 
as competing risk events, the HR for dementia was 0.91 (95% CI: 0.47 to 1.76; P = 0.781) and 0.71 (95% 
CI: 0.46 to 1.10; P = 0.124) respectively. In subsidiary analyses, we found suggestions of positive 
associations of Lp(a) with all-cause mortality and CHD, but the associations were less robust; 1.07 (95% 
CI: 0.91 to 1.25; P = 0.423) and 1.18 (95% CI: 0.97 to 1.43; P = 0.100) respectively. 
 
Comment 
In this population-based prospective study of middle-aged Finnish men, we found an approximately log-
linear inverse and independent association between Lp(a) and dementia risk. However, given the high 
mortality rate in our study cohort which might have hindered our event of interest, the association was 
attenuated when all-cause and CVD mortality were adjusted for as competing risk events. Though the 
pathogenesis of dementia is not completely understood, mechanistic research provides strong support for 
inflammatory and oxidative pathways.(11) Vascular disease is a well-recognised risk factor for 
dementia(5) and given the established role of elevated Lp(a) levels in the pathogenesis of vascular 
disease,(4) there are suggestions that increased Lp(a) levels may be associated with an increased risk of 
dementia. It therefore appears that the inverse association demonstrated in the present study is at odds 
with the biologically plausibility of the relationship. However, given the inconsistent evidence and 
controversy surrounding the relationship between Lp(a) and dementia, this may not be the case. Mooser 
and colleagues in a case-control study design, reported an increased risk of late-onset Alzheimer’s disease 
with elevated Lp(a) levels in ApoE4 carriers, with a reduced risk seen among older noncarriers of 
ApoE4.(8) In a similar case-control design, Iwamoto and colleagues also demonstrated a protective effect 
in elderly patients, but who were ApoE4 carriers. In another case-control design, Solfrizzi and colleagues 
showed a protective effect of Lp(a) among elderly patients.(6) The prospective nature of our study 
conducted in middle-aged cognitively healthy individuals at baseline offsets some of the biases in these 
previous studies and decreases the likelihood of reverse causality. However, there is a possibility that our 
results may have been overestimated, given that that the association was attenuated when competing risks 
were taken into account.  
It has been speculated that the protective effect of Lp(a) on dementia could be due to the Apo(a) 
gene,(7) which is a major determinant of plasma Lp(a) levels.(12) Sarti and colleagues postulated that 
older individuals carry the less harmful type of Lp(a) and therefore are protected from its putative 
detrimental effect on cognitive function.(9) In addition, since there might be a link between ApoE and 
Lp(a) metabolism, there is a speculation that Apo(a) alters ApoE isoform metabolism which suppresses 
changes related to the development of dementia.(7) The levels of Lp(a) in cerebrospinal fluid have been 
found to correlate strongly with plasma levels,(13) suggesting a possible role of Lp(a) in lipoprotein 
metabolism in the central nervous system and the development of neurological disorders. Just like ApoA-
I, which has been found to have a protective effect on dementia risk,(14) Lp(a) may be directly involved 
in the pathology of dementia by participating in amyloidogenesis and playing a role in neuronal 
maintenance.(15) Our findings are relevant as they indicate that elevated Lp(a) levels might be protective 
of the risk of dementia. However, given the paradoxical nature of the present findings and obvious 
limitations such as (i) low event rate; (ii) lack of generalizability of our findings because the study 
population included middle-aged Caucasian men and therefore cannot necessarily be extrapolated to 
women, other age groups and ethnicities; and (iii) lack of complete genetic data, which precluded further 
analyses such as adjusting for ApoE, a major genetic risk factor for age-related cognitive decline; (2) 
further studies are needed to replicate these results. Strengths of this study include: (i) the large sample 
that was selected to be a nationally representative population-based sample of middle-aged men; (ii) the 
high participation rate and no losses during follow-up; (iii) a long mean follow-up period; and (iv) 
adjustment for a comprehensive panel of potential confounders.  
In conclusion, Lp(a) is log-linearly and inversely associated with future risk of dementia in this 
middle-aged Finnish male population. Further research is however needed to replicate these findings and 
help unravel the mechanistic pathways linking Lp(a) and the risk of dementia.  
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Figure Legends 
 
Figure. Hazard ratios for dementia, by quartiles of baseline levels of lipoprotein(a) 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, history of coronary 
heart disease, smoking status, history of diabetes, total cholesterol, high-density lipoprotein cholesterol, 
alcohol consumption, socio-economic status, and physical activity 
  
Table. Association of baseline lipoprotein(a) with dementia 
 
 
 Events/Total Model 1  Model 2  Model 3  
Lipoprotein(a) quartiles 
(mg/dl) 
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-
value 
Hazard ratio (95% 
CI) 
P-value 
Quartile 1 (0.56-3.78) 72 / 637 Ref  Ref  Ref  
Quartile 2 (3.81-9.65) 54 / 629 0.76 (0.53 to 1.08) 0.129 0.79 (0.56 to 1.14) 0.208 0.79 (0.55 to 1.13) 0.195 
Quartile 3 (9.66-22.53) 57 / 633 0.76 (0.54 to 1.07) 0.119 0.78 (0.55 to 1.11) 0.165 0.77 (0.54 to 1.10) 0.155 
Quartile 4 (> 22.53) 45 / 633 0.68 (0.47 to 0.99) 0.044 0.68 (0.46 to 0.99) 0.044 0.68 (0.46 to 0.99) 0.045 
 
Model 1: Adjusted for age 
Model 2: Model 1 plus body mass index, systolic blood pressure, history of coronary heart disease, smoking status, history of 
diabetes, total cholesterol, high-density lipoprotein cholesterol, alcohol consumption, socio-economic status, and physical activity 
Model 3: Model 3 plus incident coronary heart disease as a time-dependent covariate 
 
 
 
 
 
 
